The Bradbury Lab is focused on co-developing and translating molecularly targeted, ultrasmall particle- and cellular engineered platforms to the clinic for image-guided surgical and theranostic applications. Our efforts build on long-standing diagnostic and therapeutic research programs at the nano-bio interface in a variety of tumor and other disease models. Specifically, our team performs translational multi-disciplinary studies to address critical unmet needs in the fields of nanomedicine, immunotherapy, radiotherapy, and image-guided surgery. Applications are both cancer and non-cancer based. We are co-developing nanomedicines and engineered cell-based therapies for clinical care, establishing favorable pharmacokinetic, safety, and efficacy profiles, regulating the tumor microenvironment, and promoting induction of cell death programs. I have, and continue to serve, as the Principal Investigator of several active Phase I/II clinical trials utilizing targeted multimodal particle-based probes for image-guided surgery in patients with prostate cancer, head and neck cancer, and malignant brain tumors.